VEGFA and retinopathy of prematurity: However, growing evidence suggests that there may be no significant difference in neurodevelopmental outcomes between ROP patients treated with anti‐VEGF or laser (Ahn et al., 2022; Celik et al., 2022; Chen et al., 2018; Chou et al., 2022; Kennedy et al., 2018; Marlow et al., 2021; Murakami et al., 2021; Natarajan et al., 2019; Raghuram et al., 2019; Rodriguez et al., 2019; Zayek et al., 2020; Zhang et al., 2020).